RT Journal Article
SR Electronic
T1 Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3541
OP 3547
VO 36
IS 7
A1 CHO, OYEON
A1 CHUN, MISON
A1 CHANG, SUK-JOON
A1 OH, YOUNG-TAEK
A1 NOH, O KYU
YR 2016
UL http://ar.iiarjournals.org/content/36/7/3541.abstract
AB Aim: To investigate whether common terminology criteria for adverse events (CTCAE) grade 4 lymphopenia (<200 cells/μl) during concurrent chemoradiotherapy (CCRT) is relevant to poor survival. Patients and Methods: We analyzed 124 patients with newly diagnosed Federation of Gynecology and Obstetrics (FIGO) stage I-III cervical cancer who received weekly cisplatin-based CCRT and brachytherapy using Kaplan-Meier curves and the Cox proportional hazard models. Results: Grade 4 lymphopenia significantly predicted disease-specific survival (DSS) and progression-free survival (PFS) (adjusted hazard ratio (95% confidence interval (CI))=3.6 (1.37-9.44), p=0.009 and 3.28 (1.27-8.48), p=0.014, respectively). The 5-year DSS and 3-year PFS were significantly higher among patients with grade 2-3 lymphopenia (≥200 cells/μl) than among those with grade 4 lymphopenia (84.8% vs. 50.4%, p<0.001, and 80.7% vs. 50%, p=0.002, respectively). Conclusion: Severe lymphopenia during CCRT could predict poor survival.